Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.34 |
| ▸ | MTOR | P42345 | 8/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25733488 | 1.00 | AR (0.34) | ARPIK3CAMTORPIK3CGPIK3R1 | |
| SCHEMBL25229561 | 0.94 | PIK3CA (0.34) | ARPIK3CAMTORPIK3CGPIK3R1 | |
| SCHEMBL31730909 | 0.89 | MAPK11 (0.35) | ROCK2ROCK1PRKD1 | |
| SCHEMBL25733532 | 0.89 | MAPK11 (0.35) | ROCK2ROCK1PRKD1 | |
| SCHEMBL25279197 | 0.87 | PIK3CA (0.34) | PIK3CAMTORPIK3CGLMNA | |
| SCHEMBL25280586 | 0.85 | GPR119 (0.44) | PIK3CAMTORPIK3CGHTT | |
| SCHEMBL31730977 | 0.79 | KDM4E (0.38) | PIK3CAROCK2ROCK1 | |
| SCHEMBL25733537 | 0.79 | KDM4E (0.38) | PIK3CAROCK2ROCK1 | |
| SCHEMBL25276103 | 0.77 | KDM4E (0.44) | — | |
| SCHEMBL31731048 | 0.76 | CNR2 (0.38) | ARPIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | AR 4818/4885PIK3CA 132/4885MTOR 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.